Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 10, 2009 - Issue 12
Submit an article Journal homepage
333
Views
15
CrossRef citations to date
0
Altmetric
Drug Evaluations

Brinzolamide/timolol fixed combination: a new ocular suspension for the treatment of open-angle glaucoma and ocular hypertension

Gábor Holló Semmelweis University, Department of Ophthalmology, 1083 Budapest, Tömö u. 25 – 29, Hungary +36 20 825 8461; +36 1 210 0309; [email protected]
,
Banu Bozkurt Selcuk University, Meram Faculty of Medicine Konya, Department of Ophthalmology, Turkey
&
Murat Irkec Hacettepe University School of Medicine, Department of Ophthalmology, Ankara, Turkey
Pages 2015-2024 | Published online: 20 Jul 2009

Bibliography

  • Quigley HA. New paradigms in the mechanisms and management of glaucoma. Eye 2005;19:1241-8
  • Quigley HA. Glaucoma: macrocosm to microcosm. Invest Ophthalmol Vis Sci 2005;46:2663-70
  • Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006;90:262-7
  • Weston BC, Aliabadi Z, White GL. Glaucoma – review for the vigilant clinician. Clin Rev 2000;10:59-74
  • Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004;363:1711-20
  • American Academy of Ophthalmology, Glaucoma Panel. Primary open-angle glaucoma. Preferred practice pattern. San Francisco. Am Acad Ophthalmol 2000:1-36
  • Rivera JL, Bell NP, Feldman RM. Risk factors for primary open-angle progression: what we know and what we need to know. Curr Opin Ophthalmol 2008;19:102-6
  • Mao LK, Stewart WC, Shields MB. Correlation between intraocular pressure control and progressive glaucomatous damage in primary open-angle glaucoma. Am J Ophthalmol 1991;111:51-5
  • Odberg T. Visual field prognosis in advanced glaucoma. Acta Ophthalmol Scan 1987;65(Suppl 182):27-9
  • The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol 2001;132:311-20
  • Leske MC, Heijl A, Hyman L, et al. Predictors of long-term progression in the early manifest glaucoma trial. Ophthalmology 2007;114:1965-72
  • Singh K, Shristava A. Intraocular pressure fluctuations: how much do they matter? Curr Opin Ophthalmol 2009;20:84-7
  • Tsai JC, Kanner EM. Current and emerging medical therapies for glaucoma. Expert Opin Emerg Drugs 2005;10:109-18
  • Radius RL, Diamond GR, Pollack IP, Langham ME. Timolol. A new drug for management of chronic simple glaucoma. Arch Ophthalmol 1978;96:1003-8
  • Schuman JS. Antiglaucoma medications: a review of safety and tolerability issues related to their use. Clin Ther 2000;22:167-208
  • Zimmerman TJ. Topical ophthalmic beta blockers: a comparative review. J Ocul Pharmacol Ther 1993;9:373-84
  • European Glaucoma Society. Terminology and Guidelines for Glaucoma. 3rd edition. Savona, Italy: Dogma srl, 2008
  • Iester M. Brinzolamide. Expert Opin Pharmacother 2008;9:1-10
  • Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13
  • Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79
  • Lichter PR, Musch DC, Gillespie BW, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
  • The AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): the relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 2000;130:429-40
  • Dunker S, Schmucker A, Maier H, et al. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther 2007;24:376-86
  • Konstas AG, Maskaleris G, Gratsonidis S, et al. Compliance and viewpoint of glaucoma patients in Greece. Eye 2000;14:752-6
  • Tsai JC. Medication adherence in glaucoma: approaches for optimizing patient compliance. Curr Opin Ophthalmol 2006;17:190-5
  • Khouri AS, Realini T, Fechtner RD. Use of fixed-dose combination drugs for the treatment of glaucoma. Drugs Aging 2007;24:1007-16
  • Olthoff CMG, Schouten JSAG, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005;112:953-61
  • Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology 2004;111:2186-92
  • Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol 2002;86:418-23
  • Dogan AS, Orhan M, Soylemezoglu F, et al. Effects of topical antiglaucoma drugs on apoptosis rates of conjunctival epithelial cells in glaucoma patients. Clin Experiment Ophthalmol 2004;32:62-6
  • Baudouin C. Detrimental effect of preservatives in eye drops: implications for the treatment of glaucoma. Acta Ophthalmol 2008;86:716-26
  • Fechtner RD, Realini T. Fixed combinations of topical glaucoma medications. Curr Opin Ophthalmol 2004;15:132-5
  • Choudhri S, Wand M, Shields MB. A comparison of dorzolamide–timolol combination versus the concomitant drugs. Am J Ophthalmol 2000;130:832-3
  • Gugleta K, Orgül S, Flammer J. Experience with Cosopt, the fixed combination of timolol and dorzolamide, after switch from free combination of timolol and dorzolamide, in Swiss ophthalmologists' offices. Curr Med Res Opin 2003;19:330-5
  • Bacharach J, Delgado MF, Iwach AG. Comparison of the efficacy of the fixed combination timolol/dorzolamide versus concomitant administration of timolol and dorzolamide. J Ocul Pharmacol Ther 2003;19:93-6
  • Holló G. Brinzolamide/timolol fixed combination for open-angle glaucoma and ocular hypertension. Exp Rev Ophthalmol 2009;4:129-33
  • Manni G, Denis P, Chew P, et al. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2009;18:293-300
  • European Agency for the Evaluation of Medical Products. European public assessment report and product information on Azarga (online). Available from: http://www.emea.europa.eu/humandocs/Humans/EPAR/azarga/azarga.htm [Last accessed 25 April 2009]
  • Sall K. Brinzolamide Primary Therapy Study Group. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt®) as a primary therapy in patients with open-angle glaucoma or ocular hypertension. Surv Ophthalmol 2000;44:S155-62
  • Cvetkovic RS, Perry CM. Brinzolamide. A review of its use in the management of primary open-angle glaucoma and ocular hypertension. Drugs Aging 2003;20:919-47
  • Desantis L. Preclinical overview of brinzolamide. Surv Ophthalmol 2000;44:S119-29
  • Maren TH. Carbonic anhydrase: chemistry, physiology, and inhibition. Physiol Rev 1967;47:595-781
  • Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. Ann Rev Biochem 1995;64:375-401
  • Wistrand PJ, Schenholm M, Lonnerholm G. Carbonic anhydrase isoenzymes CA I and CA II in the human eye. Invest Ophthalmol Vis Sci 1986;27:419-28
  • Sugrue MF. Pharmacological and ocular hypotensive properties of topical carbonic anhydrase inhibitors. Prog Retin Eye Res 2000;19:87-112
  • Pfeiffer N. Carbonic anhydrase: pharmacology and inhibition. In: Orgül S, Flammer J, editors, Pharmacotherapy in glaucoma. Bern: Hans Huber Verlag, 2000. p. 13743
  • Holló G. The use of topical carbonic anhydrase inhibitors in glaucoma treatment. In: Orgül S, Flammer J, editors. Pharmacotherapy in glaucoma. Bern: Hans Huber Verlag, 2000. p. 145-52
  • Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol 1999;128:292-6
  • Wax MB, Molinoff PB. Distribution and properties of beta adrenergic receptors in human iris/ciliary body. Invest Ophthalmol Vis Sci 1987;28:420-30
  • Nathanson JA. Effects of potent beta-adrenoceptor antagonist on intraocular pressure. Br J Pharmacol 1981;73:97-100
  • Bron AJ, Chidlow G, Melena J, Osborne NN. Beta blockers in the treatment of glaucoma. In: Orgül S, Flammer J, editors, Pharmacotherapy in glaucoma. Bern: Hans Huber Verlag, 2000. p. 79-113
  • Moss AP, Ritch R, Harpelt NA, et al. A comparison of the effects of timolol and epinephrine on intraocular pressure. Am J Ophthalmol 1978;86:489-95
  • Zimmerman TJ, Kass MA, Yablonski ME, Becker B. Timolol maleate: efficacy and safety. Arch Ophthalmol 1979;97:656-8
  • Zimmerman TJ, Kaufman H. Timolol: dose response and duration of action. Arch Ophthalmol 1977;95:605-7
  • Passo MS, Palmer EA, van Buskirk EM. Plasma timolol in glaucoma patients. Ophthalmology 1984;91:1361-3
  • Alvan G, Calissendorff BM, Seideman P, et al. Absorption of ocular timolol. Clin Pharmacokinet 1980;5:95-100
  • Tocco DJ, Duncan AE, Delauna FA, et al. Physiological disposition and metabolism of timolol in man and laboratory animals. Drug Metab Dispos 1975;3:361-70
  • Silver LH. Brinzolamide Primary Tharepy Study Group. Clinical efficacy and safety of Brinzolamide (Azopt™), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Am J Ophthalmol 1998;126:400-8
  • Shin D. Brinzolamide Adjunctive Therapy Study Group. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt®) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy. Surv Ophthalmol 2000;44(Suppl 2):S163-8
  • Rouland JF, Le Pen C, Pinto CG, et al. Cost-minimization study of dorzolamide versus brinzolamide in the treatment of ocular hypertension and primary open-angle glaucoma. In four European countries. Pharmacoeconomics 2003;21:201-13
  • March WF, Ochsner KI. Brinzolamide Study Group. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2000;129:136-43
  • Kaback M, Stephen V, Scoper SV, et al. Intraocular pressure-lowering efficacy of brinzolamide 1%/timolol 0.5% fixed combination compared with brinzolamide 1% and timolol 0.5%. Ophthalmology 2008;115:1728-34
  • Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 1998;105:1952-9
  • Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology 1998;105:1945-51
  • Strohmaier K, Snyder E, Dubiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the concomitant administration of its components. Ophthalmology 1998;105:1936-44
  • Miura K, Ito K, Okawa C, et al. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma 2008;17:233-7
  • Holló G, Chiselita D, Petkova N, et al. The efficacy and safety of timolol maleate 0.5% versus brinzolamide 1% each given twice daily added to travoprost 0.004% in patients with ocular hypertension or primary open-angle glaucoma. Eur J Ophthalmol 2006;166:816-23
  • Holló G, Kóthy P. Intraocular pressure reduction with travoprost/timolol with and without adjunctive brinzolamide, in glaucoma. Curr Med Res Opin 2008;24:1755-61
  • Harris A, Rechtman E, Siesky B, et al. The role of optic nerve blood flow in the pathogenesis of glaucoma. Ophthalmol Clin N Am 2005;18:345-53
  • Siesky B, Harris A, Brizendine E, et al. Literature review and meta-analysis of topical carbonic anhydrase inhibitors and ocular blood flow. Surv Ophthalmol 2009;54:33-46
  • Siesky B, Harris A, Cantor LB, et al. A comparative study of the effects of brinzolamide and dorzolamaide on retinal oxygen saturation and ocular microcirculation in patients with primary open-angle glaucoma. Br J Ophthalmol 2008;92;500-4
  • Vold SD, Evans RM, Stewart RH, et al. A one-week comfort study of BID-dosed brinzolamide 1% /timolol0.5% ophthalmic suspension fixed combination to BID-dosed dorzolamide 2 % /timolol 0.5% ophthalmic solution in patients with open-angle glaucoma or ocular hypertension. J Ocular Pharmacol Ther 2008;24:601-5
  • Munford TK, Rauchman SH, Williams RD, et al. A patient preference comparison of azarga (brinzolamide/timolol fixed combination) vs cosopt (dorzolamide/timolol fixed combination) in patients with open-angle glaucoma or ocular hypertension. Clin Ophthalmol 2008;2:623-8
  • Merck & Co., Inc. Cosopt (dorzolamide 2%/timolol 0.5%fixed combination) prescribing information, 2006
  • Alcon Laboratories, Inc. Azopt (brinzolamide) prescribing information, 2003
  • Stewart WC, Day DG, Stewart JA, et al. Short-term ocular tolerability of dorzolamide 2% and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjects. Eye 2004;18:905-10
  • Silver LH. Ocular comfort of brinzolamide 1.0% ophthalmic suspension compared with dorzolamide 2.0% ophthalmic solution: results from two multicenter comfort studies. Surv Ophthalmol 2000;44(Suppl 2):S141-5
  • Tsai JC, Mcclure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
  • Nordmann JP, Denis P, Vigneux M, et al. Development of the conceptual framework for the Eye-Drop Satisfaction Questionnaire (EDSQ) in glaucoma using a qualitative study. BMC Health Serv Res 2007;7:124

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.